Aims: To provide a model-based prediction of individual urinary glucose excretion (UGE) effect of ipragliflozin, we constructed a pharmacokinetic/ pharmacodynamic (PK/PD) model and a population PK model using pooled data of clinical studies.
| INTRODUCTION
Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors are a novel class of drug that inhibit the reabsorption of glucose from the kidneys and stimulate urinary glucose excretion, thereby lowering blood glucose levels in patients with type 2 diabetes mellitus (T2DM).
1 Ipragliflozin (Suglat) is a SGLT2-selective inhibitor 2 codeveloped by Astellas Pharma Inc. and Kotobuki Pharmaceutical
Co., Ltd. for the treatment of T2DM, and has been approved in Japan and Korea. In Japan, use as monotherapy or in combination with antihyperglycaemic agents (metformin, pioglitazone, sulfonylureas, α-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors, meglitinides, glucagon-like peptide-1 agonists or insulin) at a 50-mg dose once daily before or after breakfast have been approved. The dosage can be increased to 100 mg once daily if the efficacy of the 50 mg dose is insufficient. In Korea, use as monotherapy or in combination with metformin, pioglitazone or add on treatment with combination of metformin and sitagliptin have been approved, and the recommended oral dosage is 50 mg once daily before or after breakfast.
In phase I and clinical pharmacology studies in Japanese healthy subjects and patients with T2DM, ipragliflozin was consistently well tolerated, and exposure and urinary glucose excretion (UGE) were found to increase dose-dependently. [3] [4] [5] In a 12-week phase II study, dose-dependent decreases in fasting plasma glucose (FPG) and glycosylated haemoglobin (HbA1c) levels were observed when ipragliflozin was given by once daily administration at 12.5, 25, 50 and 100 mg. 6 In a phase III study in Japanese patients with T2DM (BRIGHTEN Study), ipragliflozin was well tolerated on once daily administration at 50 mg for 16 weeks. 7 Ipragliflozin was superior to a placebo in decreasing FPG and HbA1c levels, with lowering body weight and blood pressure. 7 The long-term safety and efficacy of ipragliflozin have been established in phase III studies in T2DM patients. 8, 9 By contrast, in T2DM patients with moderate renal impairment, a weaker antidiabetic effect was reported. 9 The pharmacokinetics (PK) of ipragliflozin is characterized by high oral bioavailability (>90%), 10 high protein binding ex vivo (~96%), 11 a major metabolic pathway of glucuronidation by multiple UDPglucuronosyltransferases 12, 13 and a very low urinary excretion ratio of unchanged ipragliflozin (approximately 1%). [3] [4] [5] The aim of this study was to provide a model-based prediction method for the PK/pharmacodynamics (PD) of ipragliflozin and to determine factors that influence the pharmacological effect on UGE in Japanese patients with T2DM.
2 | METHODS
| Study design
The exposure of ipragliflozin and urine glucose excretion data from the phase I study in healthy subjects (Study A) and the clinical pharmacology studies in T2DM patients (Studies B and C) were used to establish the PK/PD model of ipragliflozin. The PK data from 6 clinical studies What is already known about this subject
• Primary results of all clinical trials used in the article have been reported.
• Pharmacokinetic (PK) and pharmacodynamic (PD) results of ipragliflozin in phase I and clinical pharmacology studies have been reported in the individual clinical study reports.
• A mechanistic PK/PD model based on the European clinical data of ipragliflozin in healthy subjects and type 2 diabetes mellitus (T2DM) patients has been reported (AAPS J 12(S2): R6400, 2010).
What this study adds
• We have developed an integrated PK/PD model of ipragliflozin in Japanese healthy subjects and patients with T2DM to predict UGE by the exposure of ipragliflozin.
• We have constructed a population PK model for ipragliflozin in Japanese patients with T2DM to estimate ipragliflozin exposure.
• The developed PK/PD and population PK models enable individual predictions of UGE, which will help develop a subsequent exposure-response model for the long-term antidiabetic effects of ipragliflozin.
Harmonization Good Clinical Practice guidelines, and were approved by an institutional review board. All subjects provided written informed given by once daily oral administration at 50 mg, which was increased to 100 mg in subjects who met the dose-escalation criteria at 20 weeks after the start of ipragliflozin treatment. Blood samples for measurement of predose plasma ipragliflozin concentration were collected every 4 weeks from 4 to 52-week assessment visits.
Study G (CL-0072, NCT01316094, Long-term study with renal impairment patients) 9 was a 52-week study to assess the long-term safety and efficacy of ipragliflozin. T2DM patients with mild or moderate renal impairment who were currently on diet/exercise therapy alone or in combination with an α-glucosidase inhibitor, a sulfonylurea, or pioglitazone in a constant dosing were randomized in the study. 
| Assay for plasma levels of ipragliflozin
The concentrations of unchanged ipragliflozin in plasma were measured by liquid chromatography-tandem mass spectrometry. The lower limit of quantification was 1 ng/mL when 0.2 mL plasma was used. 14 
| Statistical methods
Descriptive statistics were calculated, including mean, standard deviation and range for continuous variables. Frequencies and percentages were calculated for categorical data. Simulation results were summarized by median and the prediction interval. All statistical data processing and summarization were performed using SAS version 9.1 and R 
Interindividual variability (η) in E max or EC 50 was not modelled because only 1 or 2 ΔUGE 24h data per subject were available. and peripheral (V p /F) compartments (TRANS4). Interindividual variability (η) for all the PK parameters and the residual random error (ε) were assumed to be log-normal and proportional, respectively.
This base model was then utilized as a prior for the analyses of trough concentration data from the 4 late-phase studies (studies D-G) using NONMEM $PRIOR subroutine. The degree of freedom (ν) of omega (Ω) prior (the degree of informativeness about Ω) was set to N -λ, where N is the number of patients utilized to establish the prior model and λ is the number of parameters. 15 Covariates were explored for CL/F regarding the following variables: age, sex, body weight, body mass index, BSA at baseline, aspartate amino transferase, alanine amino transferase, alkaline phosphatase, serum albumin, total protein (TPRO), total bilirubin (TBIL), GFR, and food effect at each assessment visit and treatment visit. Addition of covariate candidates was assessed by a stepwise manner, with statistical significance of P < .05 and backward deletion applied at P < .001.
| Model evaluation
Models were evaluated by assessing goodness-of-fit (GOF) plots. Predictive performance of the final PopPK model was evaluated by visual prediction check (VPC) with using individual demographic data from 887 T2DM patients in the analysis dataset. Robustness of the final PK/PD and PopPK models was assessed by nonparametric bootstrap.
| Simulation
The steady-state PK/PD profiles of ipragliflozin at once daily administration of 12.5, 25, 50 and 100 mg were simulated for 887 Japanese patients with T2DM enrolled in the 6 clinical studies (Studies B-G).
AUC 24h was calculated using individual post-hoc CL/F from the final PopPK model and UGE 24h was simulated by the final PK/PD model.
The effect of renal function on the exposure of plasma ipragliflozin was also investigated.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 27 
| Model evaluation
In the final PK/PD model, GOF plots suggest acceptable model fittings ( Figure S1 ). The predicted mean and the 95% confidence interval in VPC plot shows that E max curve is reproducible ( Figure S2 ). In the final PopPK model, GOF plots also suggest acceptable model fittings. The conditional weighted residuals showed no trend against time, visit or dose ( Figure S3) . And, the model enables to predict individual AUC 24h reliably ( Figure S4 ). VPC plots demonstrated that the final PopPK model well reproduced the observed data regardless of dose ( Figure 4) . The success rate of bootstrap runs was 100% of 300 runs for both the PK/PD model and PopPK models. The summary statistics of the bootstrap estimates were consistent with the parameter estimates of the final model, suggesting the robustness of the estimates. FIGURE 2 Relationship between change in urinary glucose excretion for 24 hours (ΔUGE 24h ) and A, fasting plasma glucose (FPG) and B, glomerular filtration rate (GFR) at baseline. Green circles: healthy subjects (ipragliflozin), black circles: healthy subjects (placebo), red circles: type 2 diabetes mellitus (T2DM) patients (ipragliflozin), yellow circles: T2DM patients (placebo), filled circles: patients with significantly high baseline UGE 24h (>50 g), red dotted line: locally weighted scatterplot smoothing line in T2DM patients (ipragliflozin)
| Simulation
Simulated median and the 95% prediction interval (2.5 th -97.5 th percentiles) of AUC 24h and ΔUGE 24h at steady state for each treatment are summarized in Table 4 and Figure 5 . The effect of renal function on the exposure of plasma ipragliflozin at steady state was also investigated with once daily administration at 50 mg ( Table 5 ). The simulation suggested a 1.17-fold increase in AUC 24h of ipragliflozin and a 0.76-fold change in ΔUGE 24h in T2DM patients with moderate renal impairment (eGFR: 30 to <60 mL/min/1.73m
2 ) compared to those with normal renal function.
| DISCUSSION
The developed PK/PD model described the relationship between the individual plasma ipragliflozin exposure (AUC 24h ) and ΔUGE 24h as a pharmacological effect of ipragliflozin. The PopPK model was developed in order to assess the individual AUC 24h in patients with T2DM from sparse PK samples. In a previous publication, we described increase in UGE using an E max model predicted by AUC 24h and the initial excretion level (E0). 20 In the model, however, the impact of renal function on UGE was not considered, thus the E max need to be estimated separately for healthy subjects and patients with T2DM.
The new model established in this article provides the mechanismbased pharmacological effect of SGLT2 inhibitor both healthy subjects and patients with T2DM in 1 model by taking into consideration the individual FPG and GFR.
In healthy individuals, about 180 g of glucose (calculated as the primitive urine production of 180 L/24 h times the normal FPG level of 100 mg/dL) is filtered daily at the renal glomeruli and nearly 100% of filtered glucose is reabsorbed at the renal tubules. 19 In other words, both FPG and GFR are determinative factors of UGE. SGLT2 is expressed at the renal proximal tubules and accounts for over 90% of renal glucose reabsorption. 21 When the blood glucose level is higher than the maximum capacity of reabsorption (approximately 180 mg/dL), glucose is then excreted into urine. Beyond the threshold, urinary glucose increases in a linear fashion with increasing plasma glucose level. 18, 19 SGLT2 inhibitors lower the maximum capacity of glucose reabsorption.
The relationship between FPG, GFR and UGE are clearly indicated by the observed clinical data taken from patients with ipragliflozin in studies A, B and C, which are schematically presented in Figure 3 .
The figure shows that the threshold value for reabsorption at baseline used in the PK/PD modelling (FPG × GFR = 18 000 or 180 g/24 h) is physiologically adequate if considering the pharmacological effect of SGLT2 inhibitors. As obvious based on the mechanism, the maximum effect on UGE of SGLT2 (ΔUGE 24h ) never exceeds filtered glucose. Therefore, E max of ΔUGE 24h was parameterized by product of FPG and GFR in this article.
In the PK/PD analysis, the estimated E max was 140 g/24 h in Japanese T2DM patients with the reference FPG (160 mg/dL) and GFR (90 mL/min). A comparable E max for empagliflozin (120 g/24 h) was reported in T2DM patients with a mean FPG of 8-9 mmol/L (144-162 mg/dL). 22 The E max of these SGLT2 inhibitors are estimated to be about 40-50% compared to total amount of filtered glucose (288 g: FPG 160 mg/dL × primitive urine production: 180 L/24 h).
The absence of complete inhibition of urinary glucose reabsorption was also found even under the condition with almost no SGLT2 activity expected to be remained in empagliflozin and dapagliflozin studies. 22, 23 The incomplete inhibition mainly attributes to contribution of reabsorption by SGLT1 expressed in the luminal membrane of the late proximal tubule. 24, 25 The final PopPK model indicates fixed effects of BSA, GFR, TPRO and TBIL as statistically significant covariates on ipragliflozin exposure.
GFR is thought to be a dominant factor to affect ipragliflozin exposure, whereas the other covariates will cause only 10% or less change in the By contrast, the PK/PD model suggests that glucose excretion effect almost reaches the maximum level at above 50 mg daily dose of iplagliflozin. Based on the established PK/PD model, it is suggested that any excessive drug effect cannot be expected in renal impairment patients due to the higher exposure caused by renal impairment. In addition, lower GFR in renal impairment patients results in lower urinary filtrated glucose; therefore, the drug effect (ΔUGE 24h ) by ipragliflozin is lower. Our model well described the result of the lower UGE in renal impairment patients with T2DM found in study C. 5 Furthermore, the lower decrease in FPG and HbA1c by ipragliflozin was confirmed in the long-term study in renal impairment patients (study G). 9 Recently, de Winter et al. reported a dynamic PK/PD model for HbA1c decreasing effect of canagliflozin. 26 In this report, GFR was a significant covariate of E max and the outcome was simulated by normalized HbA1c level at baseline. The results are consistent with our findings, and it also supports our assumption that UGE effect by 
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